V Medina-Villaamil1, S Martínez-Breijo2, P Portela-Pereira2, M Quindós-Varela3, I Santamarina-Caínzos4, L M Antón-Aparicio5, F Gómez-Veiga2. 1. Instituto de Investigación Biomédica, A Coruña, INIBIC, CHU A Coruña-XXIAC, A Coruña, España. Electronic address: Vanessa.medina.villaamil@sergas.es. 2. Servicio de Urología Médica, CHU A Coruña-XXIAC, A Coruña, España. 3. Servicio de Oncología Médica, CHU A Coruña-XXIAC, A Coruña, España. 4. Instituto de Investigación Biomédica, A Coruña, INIBIC, CHU A Coruña-XXIAC, A Coruña, España. 5. Servicio de Oncología Médica, CHU A Coruña-XXIAC, A Coruña, España; Departamento de Medicina, Universidade da Coruña, UDC, A Coruña, España.
Abstract
INTRODUCTION: MicroRNAs (miRNAs) are small regulatory RNAs that do not code for proteins. Detection of circulating tumor cells (CTC) would provide diagnostic and prognostic information in prostate tumors (PT). Thus, miRNAs could constitute a promising new class of biomarkers for CTC detection. OBJECTIVES: To analyze circulating microRNAs in whole blood as non-invasive markers in patients with localized prostate cancer and healthy individuals. MATERIAL AND METHODS: A preliminary study including a population of 40 patients with mean age of 71 years and mean PSA of 18, 9 ng/ml (range). Regarding the risk group (RG): 33.3% had low risk, 30% intermediate risk and 36.7% high risk. A previous in silico study identified 92 candidates and was followed by another in vivo to verify the findings of the former using array technology by real-time PCR. RESULTS: Statistical analysis of the results revealed 10 microRNAs candidates with statistically significant differential expression between the different risk groups and healthy controls: hsa-miR-337-3p, hsa-miR-330-3p, hsa-miR-339-3p, hsa-miR-124, hsa-miR-218, hsa-miR-128, hsa-miR-10a, hsa-miR-199b-5p, hsa-miR-200b and hsa-miR-15b. CONCLUSIONS: Our data suggest that circulating microRNAs can act as biomarkers to identify risk groups in CaP.
INTRODUCTION: MicroRNAs (miRNAs) are small regulatory RNAs that do not code for proteins. Detection of circulating tumor cells (CTC) would provide diagnostic and prognostic information in prostate tumors (PT). Thus, miRNAs could constitute a promising new class of biomarkers for CTC detection. OBJECTIVES: To analyze circulating microRNAs in whole blood as non-invasive markers in patients with localized prostate cancer and healthy individuals. MATERIAL AND METHODS: A preliminary study including a population of 40 patients with mean age of 71 years and mean PSA of 18, 9 ng/ml (range). Regarding the risk group (RG): 33.3% had low risk, 30% intermediate risk and 36.7% high risk. A previous in silico study identified 92 candidates and was followed by another in vivo to verify the findings of the former using array technology by real-time PCR. RESULTS: Statistical analysis of the results revealed 10 microRNAs candidates with statistically significant differential expression between the different risk groups and healthy controls: hsa-miR-337-3p, hsa-miR-330-3p, hsa-miR-339-3p, hsa-miR-124, hsa-miR-218, hsa-miR-128, hsa-miR-10a, hsa-miR-199b-5p, hsa-miR-200b and hsa-miR-15b. CONCLUSIONS: Our data suggest that circulating microRNAs can act as biomarkers to identify risk groups in CaP.
Keywords:
Cáncer de próstata; MicroARN; MicroRNAs; Micrometastasis; Micrometástasis; Polymerase chain reaction; Prostate cancer; Reacción en cadena de la polimerasa
Authors: Frank Qian; Ye Feng; Yonglan Zheng; Temidayo O Ogundiran; Oladosu Ojengbede; Wei Zheng; William Blot; Christine B Ambrosone; Esther M John; Leslie Bernstein; Jennifer J Hu; Regina G Ziegler; Sarah Nyante; Elisa V Bandera; Sue A Ingles; Michael F Press; Katherine L Nathanson; Anselm Hennis; Barbara Nemesure; Stefan Ambs; Laurence N Kolonel; Olufunmilayo I Olopade; Christopher A Haiman; Dezheng Huo Journal: Hum Genet Date: 2016-07-05 Impact factor: 4.132